source
- Epicrispr secures $90M Series C to advance epigenetic therapy for rare muscle diseaseEpicrispr Biotechnologies announced a $90 million Series C financing round, led by Octagon Capital and Janus Henderson Investors, with participation from Sanofi Ventures and other investors. The c…
- Experts warn splitting MMR vaccine into separate shots could increase missed doses and illnessThe article notes that a recent executive order proposes separating the combined measles, mumps and rubella vaccine into three individual injections. The author argues that this change could lead t…